The Hook: Less Pomegranate, Better Skin Signals
Most supplement logic says more is more. This trial of a pomegranate extract pill called Pomanox pointed the other way. The lower dose, 367 mg, produced the most interesting skin signals, while the 700 mg dose mostly lagged behind it. Before you order a bottle, there's a catch: the study's main goal, shrinking a facial dark spot, did not hit statistical significance.
Here is what the trial showed, what it didn't, and how to read it like a skeptical biohacker.
What the Study Did
This is a human randomized controlled trial, not an animal or cell-culture study. It was published in Scientific Reports in 2026 and was randomized, triple-blind and placebo-controlled.
- Who: Women aged 30-65 with Fitzpatrick skin phototypes II-IV and at least one facial hyperpigmented spot.
- What: Pomanox P30, a standardized pomegranate (Punica granatum L.) fruit extract rich in punicalagins. It is made by Euromed.
- Doses: 367 mg or 700 mg, versus placebo.
- How long: 12 weeks of oral supplementation.
- What was measured: The melanin index (MI) of a facial spot, hydration, elasticity, skin-related serum and urine biomarkers, and the facial and gut microbiota.
What It Found
The primary endpoint missed. The pre-specified main outcome was the group-by-visit interaction for the melanin index of a facial spot. At 12 weeks it came in at P = 0.158, well above the usual 0.05 cutoff. By the trial's own standard, pomegranate did not significantly change spot pigmentation over time.
The rest of the findings come from secondary, exploratory analyses:
- Dark spot (367 mg): A significant decrease in the percentage change of the spot's melanin index versus placebo (P < 0.05).
- Hydration (367 mg): A significant increase versus placebo (P < 0.05).
- Elasticity (both doses): Both 367 mg and 700 mg increased skin elasticity versus placebo (P < 0.05).
- Microbiota: Nominal shifts in selected skin and gut taxa, including Lacticaseibacillus genera with the 367 mg dose.
The abstract reports significance thresholds, not effect sizes, so I can't tell you how many "points" of elasticity or hydration changed. The dose pattern is what stands out. The lower dose carried more of the exploratory wins, and only elasticity improved at both doses.
The Catch: Why You Should Stay Skeptical
- The primary endpoint failed. Positive secondary results after a missed primary are hypothesis-generating, not proof. The authors say so themselves.
- Exploratory means multiple looks. Test enough outcomes and some will cross P < 0.05 by chance.
- The dose pattern is odd. A lower dose outperforming a higher one could reflect absorption limits, individual variation in gut metabolism, or simple noise. The data can't distinguish these.
- The microbiota data are preliminary. The authors describe the changes as "nominal" and say confirmation requires studies powered for microbiota outcomes.
- Industry link. The extract is a commercial ingredient from Euromed. That doesn't invalidate the trial, but it's context.
- Narrow population. Women 30-65 with phototypes II-IV. The results don't tell us about men, very light or very dark skin, or other age groups.
- Only 12 weeks. There is no information on durability or long-term safety from this paper.
The authors conclude that the 367 mg dose may benefit specific skin parameters, and that powered studies are needed to confirm it.
Why Pomegranate Is Plausible
Pomegranate is rich in ellagitannins such as punicalagins. Gut bacteria convert these into urolithins, including the much-discussed urolithin A. That makes the gut-skin angle and the microbiota readouts mechanistically interesting. This trial did not show that urolithin production explains the skin results, so treat that link as background, not a finding.
How to Use It (If You Want to Experiment)
- Dose: The better-performing dose was 367 mg of Pomanox P30. Higher didn't mean better here, so there's no evidence for megadosing.
- Form: An oral standardized extract, meaning punicalagin-defined. Juice or random "pomegranate powder" isn't the same product. Check the label for the specific extract and a stated standardization.
- Timeline: The trial ran 12 weeks. Don't judge it at week 2. Take baseline photos in consistent lighting, and reassess at about 12 weeks.
- Timing: The abstract doesn't specify time of day or whether it was taken with food. Follow the product label.
- Stack sensibly: Daily broad-spectrum sunscreen does far more for dark spots than any pill. The study doesn't say what sun protection participants used.
Who It May Suit, and Who Should Skip It
- Women roughly 30-65 with mild facial hyperpigmentation and phototypes II-IV who want to try a low-risk, food-derived supplement alongside sunscreen
- People interested in hydration and elasticity more than dramatic spot fading
- Self-trackers willing to run a 12-week n=1 experiment
Consider skipping or asking a clinician first if you:
- Are pregnant or breastfeeding, since the paper provides no data for these groups
- Take prescription medications. Pomegranate is sometimes flagged for potential drug interactions, so check with a pharmacist
- Have a changing, irregular, or dark lesion. That needs a dermatologist, not a supplement
- Expect clear melanin reduction. The primary endpoint says that isn't established
Bottom Line
Pomanox offers a tantalizing but unconfirmed signal: modest, exploratory improvements in hydration and elasticity, and a possible effect on spot pigmentation at the lower dose. Because the primary dark-spot endpoint failed, this is a "promising, now prove it" result. Until a larger, adequately powered trial replicates it, treat pomegranate extract as an optional add-on to sun protection, not a dark-spot cure. This article is informational and not medical advice.
